Functional Fluidics Pivotal Sickle Cell Disease Research Study Announced

Share this news:

Functional Fluidics in Detroit Michigan participated in a pivotal ELIPSIS study on sickle cell disease which may help predict VOCs and improve crisis intervention and drug therapies.

Functional Fluidics, a biotechnology company specializing in red blood cell health in Detroit, Michigan, announces that its biomarkers can help predict sickle cell disease vaso-occlusive crisis (VOCs) after participating in a pivotal longitudinal Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) study. Findings of the study were published in the Blood Journal by the American Society of Hematology.

The announcement addresses the need for well-validated biomarkers to objectively monitor red blood cell health in individuals with sickle cell disease at baseline, to start and monitor drug therapy progress, as well as help predict pain crisis. Findings from this ELIPSIS study offer medical providers objective red blood cell biomarkers as tools so they can focus on health maintenance rather than crisis intervention.

Sickle cell disease is a group of red blood cell disorders that cause cells to die early, causing a constant shortage of healthy red blood cells in the body. The disease also disfigures the shape of the red blood cells, which may cause other medical conditions such as infection and stroke. VOCs are the most common complication of sickle cell anemia.

Functional Fluidics participated in the study to validate their red blood cell assays and offer insights on how providers can intervene earlier for high-risk patients of a vaso-occlusive episode (VOE). Currently, around 100,000 Americans and millions worldwide are affected by frequent and unpredictable VOEs that produce severe pain, organ damage, and early death.

The ELIPSIS research study found that Functional Fluidics biomarkers can help predict sickle cell disease pain crisis and monitor drug therapy progress. Assessments on the company’s health assays found that they can be used as prognostic tools to stratify baseline patients based on their risk of developing VOCs.

The health assays may also be used as diagnostic biomarkers of adhesion-associated VOC. Watch Video

The findings of the study may provide insight into the timing of crisis resolution and may improve how medical providers treat sickle cell disease patients in an acute setting, redefining care for sickle cell disease patients.

Interested parties may find more information by visiting

Release ID: 89005871